Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chromatin accessibility complex protein 1 (CHRAC1) is a histone-fold protein that functions as an accessory subunit of ATP-dependent chromatin remodeling complexes, such as those involving ISWI/SNF2H and ACF1. CHRAC1 interacts with other histone-fold proteins to form dimers, binding DNA in a sequence-independent manner, and is essential for DNA transcription, replication, and chromatin packaging. Within larger chromatin remodeling complexes, it modulates nucleosome positioning and chromatin accessibility to influence gene expression. In cancer, CHRAC1 overexpression drives cell proliferation and survival, notably by interacting with the transcriptional coactivator YAP in the Hippo signaling pathway, thereby promoting oncogenic transcriptional programs. Its dysregulation is implicated in several cancer types and developmental disorders, indicating both its physiological importance and therapeutic potential[1][2][3][4].
Not currently targeted by specific approved drugs. Hypothetical mechanism: inhibition could suppress oncogenic transcription programs (specifically via modulation of YAP-dependent transcription in the Hippo pathway).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chromatin accessibility complex protein 1 (CHRAC1).